WASHINGTON, DC: Millstone Medical Outsourcing has accomplished the acquisition of MycoScience, on November 14, 2022.
Headquartered in Willington, Connecticut, MycoScience has over 30 years of expertise in medical device and pharmaceutical laboratory testing, environmental testing, and associated regulatory support services.
The firm is an ISO 13485:2016 licensed contract manufacturing group working out of an FDA-registered facility with a rigorous approach to high quality that will uphold Millstone’s dedication to working under the highest high quality standards.
The addition of MycoScience to Millstone brings superior laboratory and environmental testing services with longstanding industry and regulatory expertise to Millstone’s capabilities.
Post-acquisition, Millstone Medical Outsourcing can full these adjoining services for its customers in-house, with higher controls round product testing. Being able to supply these services in-house will speed up buyer time to market and reduce lead times for in-process testing inside production.
The addition of MycoScience additionally enhances Millstone’s ability to supply full end-to-end services through its Tier 1 approach to expert sourcing and support.
Matt Altman, a Managing Partner at Arlington Capital Partners, said, “MycoScience is a extremely strategic and complementary acquisition that gives Millstone with broader testing capabilities that may be leveraged throughout its buyer set. We are excited by the expansion alternatives this mixture will create for Millstone and its customers.”
“With the acquisition of MycoScience, we can offer our customers extra support and higher controls round product testing, with a single expert level of contact,” Millstone Medical Outsourcing CEO Karl Neuberger said.
“The extra superior and thorough post-manufacturing and aftermarket services we can offer our customers, the extra we can support them in creating and accelerating merchandise that change patients’ lives. This acquisition brings collectively two companies aligned on dedication to quality, expertise, and excellent buyer service.”
MycoScience’s management team will stay on the helm. MycoScience CEO Sarath Koruprolu noted, “Over the final 30 years, MycoScience has helped our customers bring amazing new devices and medicines to marketplace for higher affected person outcomes. Now, as we start a brand new chapter with Millstone, we glance ahead to persevering with to use our expertise to product testing, quality, and developments as a half of the industry partner of choice.”
Gordon Auduong, a Principal at Arlington Capital Partners, added, “MycoScience’s testing capabilities are a pure extension to Millstone’s present post-manufacturing and distribution & logistics services that will allow Millstone to present additional worth to its customers. We are excited to partner with the MycoScience administration team and proceed their spectacular growth as a half of the Millstone platform.”
Millstone Medical Outsourcing is a number one supplier of customized outsourcing options to the medical device industry with a client roster of the most prominent global OEMs in addition to rising growth companies. Millstone delivers superior high quality service, unparalleled expertise, and assured ROI.
The firm offers superior inspection, sterile and non-sterile packaging, loaner kit processing, and distribution services to device and product producers worldwide. Millstone is privately held and operates state-of-the-art facilities in Fall River, MA, and Olive Branch, MS.